BRAF and melanoma: To assess the contribution of YAP1 signaling in CAFs to BRAF-mutant melanoma progression in vivo, we generated a transgenic mouse model, α-SMA-CreERT2; Yap1loxP/loxP, which allows the inducible ablation of YAP1 expression in CAFs [11, 12].